300294 博雅生物
已收盘 05-26 15:00:00
资讯
新帖
简况
股市必读:博雅生物(300294)5月22日董秘有最新回复
证券之星 · 05-25 03:14
股市必读:博雅生物(300294)5月22日董秘有最新回复
博雅生物:公司2026年5月20日含信用账户合并名册的股东人数为31,639户
证券之星 · 05-22
博雅生物:公司2026年5月20日含信用账户合并名册的股东人数为31,639户
博雅生物:成为世界一流血液制品企业
证券之星 · 05-22
博雅生物:成为世界一流血液制品企业
股市必读:博雅生物(300294)5月15日披露最新机构调研信息
证券之星 · 05-18
股市必读:博雅生物(300294)5月15日披露最新机构调研信息
股市必读:博雅生物(300294)今年截至5月14日累计跌幅已超25%
证券之星 · 05-15
股市必读:博雅生物(300294)今年截至5月14日累计跌幅已超25%
博雅生物(300294)披露变更办公地址及投资者联系电话公告,5月13日股价下跌1.72%
证券之星 · 05-13
博雅生物(300294)披露变更办公地址及投资者联系电话公告,5月13日股价下跌1.72%
博雅生物:外延式并购存在较大不确定性
证券之星 · 05-13
博雅生物:外延式并购存在较大不确定性
博雅生物:静注人免疫球蛋白(pH4)具有免疫替代和免疫调节的双重治疗作用
证券之星 · 05-12
博雅生物:静注人免疫球蛋白(pH4)具有免疫替代和免疫调节的双重治疗作用
股市必读:博雅生物(300294)5月8日董秘有最新回复
证券之星 · 05-11
股市必读:博雅生物(300294)5月8日董秘有最新回复
博雅生物:持续深耕血液制品主业
证券之星 · 05-09
博雅生物:持续深耕血液制品主业
博雅生物:截至目前,公司暂无筹划及推进中的定增计划
证券之星 · 05-09
博雅生物:截至目前,公司暂无筹划及推进中的定增计划
博雅生物(300294)披露将参加江西辖区上市公司2026年投资者网上集体接待日活动,5月8日股价上涨2.01%
证券之星 · 05-08
博雅生物(300294)披露将参加江西辖区上市公司2026年投资者网上集体接待日活动,5月8日股价上涨2.01%
股市必读:博雅生物(300294)4月30日董秘有最新回复
证券之星 · 05-06
股市必读:博雅生物(300294)4月30日董秘有最新回复
博雅生物:2026年一季度公司营业收入、归母净利润同比下滑
证券之星 · 04-30
博雅生物:2026年一季度公司营业收入、归母净利润同比下滑
股市必读:博雅生物(300294)今年截至4月28日累计跌幅已超20%
证券之星 · 04-29
股市必读:博雅生物(300294)今年截至4月28日累计跌幅已超20%
博雅生物:持续深耕血液制品主业
证券之星 · 04-28
博雅生物:持续深耕血液制品主业
股市必读:博雅生物一季报 - 第一季度单季净利润同比下降78.33%
证券之星 · 04-27
股市必读:博雅生物一季报 - 第一季度单季净利润同比下降78.33%
博雅生物(300294)4月10日股东户数3.23万户,较上期减少0.95%
证券之星 · 04-25
博雅生物(300294)4月10日股东户数3.23万户,较上期减少0.95%
图解博雅生物一季报:第一季度单季净利润同比下降78.33%
证券之星 · 04-25
图解博雅生物一季报:第一季度单季净利润同比下降78.33%
华润医药旗下博雅生物季度营收32.11亿元 净利润达3000万元
美股速递 · 04-24
华润医药旗下博雅生物季度营收32.11亿元 净利润达3000万元
加载更多
公司概况
公司名称:
华润博雅生物制药集团股份有限公司
所属行业:
医药制造业
上市日期:
2012-03-08
主营业务:
华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、人免疫球蛋白、静注人免疫球蛋白(含10%高浓度剂型)、冻干静注人免疫球蛋白、乙肝人免疫球蛋白、破伤风免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血酶原复合物、人凝血因子Ⅷ。公司技术实力雄厚,先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项,拥有各类专利200余项,多次荣膺省、市科学技术奖和优秀新产品奖。
发行价格:
25.00
{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":15.61,"timestamp":1779778941000,"preClose":15.8,"halted":0,"volume":4569993,"delay":0,"changeRate":-0.012,"floatShares":504000000,"shares":504000000,"eps":0.0069,"marketStatus":"已收盘","change":-0.19,"latestTime":"05-26 15:00:00","open":15.7,"high":15.93,"low":15.52,"amount":71483600,"amplitude":0.0259,"askPrice":15.62,"askSize":13,"bidPrice":15.61,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.0069,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":5,"adr":0,"adjPreClose":15.8,"symbolType":"stock","openAndCloseTimeList":[[1779759000000,1779766200000],[1779771600000,1779778800000]],"highLimit":17.38,"lowLimit":14.22,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":1.07,"roa":"--","peRate":2262.318841,"roe":"0.41%","epsLYR":0.22,"committee":-0.19774,"marketValue":7871000000,"turnoverRate":0.0091,"status":1,"floatMarketCap":7871000000},"requestUrl":"/m/hq/s/300294","defaultTab":"news","newsList":[{"id":"2638302415","title":"股市必读:博雅生物(300294)5月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638302415","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638302415?lang=zh_cn&edition=full","pubTime":"2026-05-25 03:14","pubTimestamp":1779650052,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘,博雅生物报收于15.67元,下跌2.18%,换手率1.31%,成交量6.58万手,成交额1.03亿元。董秘最新回复投资者: 请问贵公司是否有意向将博雅打包出售给国药或者莱士?经查询中国证券登记结算有限责任公司的数据,公司2026年5月20日含信用账户合并名册的股东人数为31,639户。截至目前,公司暂无相关事项。如有,公司将根据证券法规及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500001333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637392583","title":"博雅生物:公司2026年5月20日含信用账户合并名册的股东人数为31,639户","url":"https://stock-news.laohu8.com/highlight/detail?id=2637392583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637392583?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:42","pubTimestamp":1779439339,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,截止5月20日,公司股东数量是多少?博雅生物回复:您好,感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据,公司2026年5月20日含信用账户合并名册的股东人数为31,639户。以上内容为证券之星据公开信息整理,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637392509","title":"博雅生物:成为世界一流血液制品企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2637392509","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637392509?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:42","pubTimestamp":1779439338,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司是否有意向将博雅打包出售给国药或者莱士?博雅生物回复:您好,感谢您对本公司的关注。公司系华润集团大健康板块的血液制品平台,始终坚持“成为世界一流血液制品企业”的战略目标。控股股东在战略管理、组织优化、人才引进、风险管理及政府资源的嫁接等各方面,给予了公司极大的支持与赋能,为公司长远、稳定发展奠定了坚实的基础。以上内容为证券之星据公开信息整理,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636166040","title":"股市必读:博雅生物(300294)5月15日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2636166040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636166040?lang=zh_cn&edition=full","pubTime":"2026-05-18 03:53","pubTimestamp":1779047589,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,博雅生物报收于16.45元,下跌1.61%,换手率1.11%,成交量5.62万手,成交额9328.77万元。公司公告汇总关于公司董事暨副总裁辞任的公告华润博雅生物制药集团股份有限公司董事会于2026年5月15日收到董事、副总裁梁化成先生的书面《辞任报告》。截至公告披露日,梁化成先生未持有公司股份,不存在应履行而未履行的承诺事项,辞任报告自送达董事会之日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800001598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635747112","title":"股市必读:博雅生物(300294)今年截至5月14日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635747112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635747112?lang=zh_cn&edition=full","pubTime":"2026-05-15 02:23","pubTimestamp":1778782990,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘,博雅生物报收于16.72元,下跌2.62%,换手率1.18%,成交量5.96万手,成交额1.01亿元。当日关注点来自交易信息汇总:博雅生物股价已连续6日下跌,当年累计跌幅达25.42%。交易信息汇总股价提醒5月14日博雅生物收盘报16.72元,跌2.62%,当日成交595.71万元。资金流向5月14日主力资金净流出1347.51万元;游资资金净流入10.59万元;散户资金净流入1336.92万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500001904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635733159","title":"博雅生物(300294)披露变更办公地址及投资者联系电话公告,5月13日股价下跌1.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635733159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635733159?lang=zh_cn&edition=full","pubTime":"2026-05-13 22:23","pubTimestamp":1778682197,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘,博雅生物报收于17.17元,较前一交易日下跌1.72%,最新总市值为86.58亿元。该股当日开盘17.53元,最高17.54元,最低17.1元,成交额达1.05亿元,换手率为1.2%。近日,华润博雅生物制药集团股份有限公司发布《关于变更办公地址及投资者联系电话的公告》。上述变更自公告发布之日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300045684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300294","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635787564","title":"博雅生物:外延式并购存在较大不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2635787564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635787564?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:51","pubTimestamp":1778676687,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)05月12日在投资者关系平台上答复投资者关心的问题。投资者提问:请问管理层今年有定增收购血制品企业打算吗博雅生物回复:您好,感谢您对本公司的关注。公司始终关注行业发展趋势,并聚焦有利于提升公司核心竞争力、创造长期价值的战略机会,但外延式并购存在较大不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300042410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634629619","title":"博雅生物:静注人免疫球蛋白(pH4)具有免疫替代和免疫调节的双重治疗作用","url":"https://stock-news.laohu8.com/highlight/detail?id=2634629619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634629619?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:21","pubTimestamp":1778574075,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物05月12日在投资者关系平台上答复投资者关心的问题。公司主营业务为生产和销售血液制品,主要产品为人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品等。公司生产的免疫球蛋白类产品多用于免疫性疾病治疗,传染性疾病被动免疫和治疗等。其中静注人免疫球蛋白主要用于原发性免疫球蛋白缺乏症、继发性免疫球蛋白缺陷病、自身免疫性疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200026892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0046","BK0239","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634864426","title":"股市必读:博雅生物(300294)5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634864426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634864426?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:40","pubTimestamp":1778438423,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,博雅生物报收于17.73元,上涨2.01%,换手率1.37%,成交量6.93万手,成交额1.23亿元。董秘最新回复投资者: 请问董秘,公司是否计划定增介绍下。截至目前,公司暂无筹划及推进中的定增计划。公司公告汇总公司关于参加江西辖区上市公司2026年投资者网上集体接待日活动的公告华润博雅生物制药集团股份有限公司将参加由江西省上市公司协会举办的“2026年江西辖区上市公司投资者网上集体接待日活动”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634494719","title":"博雅生物:持续深耕血液制品主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2634494719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634494719?lang=zh_cn&edition=full","pubTime":"2026-05-09 14:15","pubTimestamp":1778307311,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物05月09日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900006730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634249472","title":"博雅生物:截至目前,公司暂无筹划及推进中的定增计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2634249472","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634249472?lang=zh_cn&edition=full","pubTime":"2026-05-09 14:15","pubTimestamp":1778307310,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)05月09日在投资者关系平台上答复投资者关心的问题。投资者提问:请问董秘,公司是否计划定增介绍下。博雅生物回复:您好,感谢您对本公司的关注。截至目前,公司暂无筹划及推进中的定增计划。未来若有相关安排,公司将严格按照监管法律法规及信息披露规则,及时履行审议及公告义务。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900006729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300294","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633045796","title":"博雅生物(300294)披露将参加江西辖区上市公司2026年投资者网上集体接待日活动,5月8日股价上涨2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633045796","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633045796?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:26","pubTimestamp":1778250377,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,博雅生物报收于17.73元,较前一交易日上涨2.01%,最新总市值为89.4亿元。该股当日开盘17.39元,最高18.05元,最低17.38元,成交额达1.23亿元,换手率为1.37%。博雅生物于近日披露《公司关于参加江西辖区上市公司2026年投资者网上集体接待日活动的公告》。活动采用网络远程方式,投资者可通过“全景路演”网站、微信公众号“全景财经”或下载全景路演APP参与。活动时间为2026年5月15日15:00-17:00,公司将就投资者关心的问题进行在线交流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800043747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633923884","title":"股市必读:博雅生物(300294)4月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2633923884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633923884?lang=zh_cn&edition=full","pubTime":"2026-05-06 03:06","pubTimestamp":1778007974,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,博雅生物报收于17.48元,下跌1.35%,换手率0.83%,成交量4.17万手,成交额7327.89万元。董秘最新回复投资者: 请问董秘为什么一季度业绩怎么差?2026 年一季度公司营业收入、归母净利润同比下滑,主要受行业集采、市场竞争导致核心产品量价回落。投资者: 您好,派林生物近期公告拟实施 2-3 亿元股份回购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0046","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631903685","title":"博雅生物:2026年一季度公司营业收入、归母净利润同比下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2631903685","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631903685?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:21","pubTimestamp":1777537270,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)04月30日在投资者关系平台上答复投资者关心的问题。投资者提问:请问董秘为什么一季度业绩怎么差?原因在哪里?博雅生物回复:您好,感谢您对本公司的关注。2026 年一季度公司营业收入、归母净利润同比下滑,主要受行业集采、市场竞争导致核心产品量价回落。公司会围绕战略目标,紧扣行业政策导向与市场发展形势,持续精进经营管理、夯实运营根基,促进公司健康可持续发展。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000053162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631629537","title":"股市必读:博雅生物(300294)今年截至4月28日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631629537","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631629537?lang=zh_cn&edition=full","pubTime":"2026-04-29 06:56","pubTimestamp":1777416992,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘,博雅生物报收于17.57元,下跌2.12%,换手率1.01%,成交量5.07万手,成交额8978.3万元。交易信息汇总股价提醒4月28日博雅生物收盘报17.57元,跌2.12%,当日成交507.2万元。该股已连续4日下跌,当年累计跌幅20.42%。前10个交易日主力资金累计净流出6143.92万元,股价累计下跌5.61%;融资余额累计减少664.04万元,融券余量累计增加400股。过去90天内共有5家机构对该股给出评级,其中买入评级4家,增持评级1家,机构目标均价为20.51元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900017181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0239","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630379552","title":"博雅生物:持续深耕血液制品主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2630379552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630379552?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:57","pubTimestamp":1777366627,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物04月28日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,关注到公司26年一季度营收和利润同比下滑,且拟出售南京新百药业,进一步聚焦血液制品主业。面对血液制品行业深度调整与转型压力,公司将持续深耕血液制品主业,多措并举夯实发展根基,持续蓄力厚植增长动能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800049975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331416","title":"股市必读:博雅生物一季报 - 第一季度单季净利润同比下降78.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331416","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630331416?lang=zh_cn&edition=full","pubTime":"2026-04-27 06:22","pubTimestamp":1777242131,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动近日博雅生物披露,截至2026年4月10日公司股东户数为3.23万户,较3月31日减少308.0户,减幅为0.95%。公司公告汇总2026年一季度报告华润博雅生物制药集团股份有限公司2026年第一季度报告显示,本报告期营业收入为321,128,375.86元,较上年同期下降40.07%;归属于上市公司股东的净利润为30,220,896.06元,同比下降78.33%;扣除非经常性损益后的净利润为20,323,474.32元,同比下降80.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700006626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630870696","title":"博雅生物(300294)4月10日股东户数3.23万户,较上期减少0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630870696","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630870696?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:12","pubTimestamp":1777108326,"startTime":"0","endTime":"0","summary":"证券之星消息,近日博雅生物披露,截至2026年4月10日公司股东户数为3.23万户,较3月31日减少308.0户,减幅为0.95%。在生物制品行业个股中,博雅生物股东户数低于行业平均水平,截至4月10日,生物制品行业平均股东户数为3.6万户。从股价来看,2026年3月31日至2026年4月10日,博雅生物区间涨幅为1.56%,在此期间股东户数减少308.0户,减幅为0.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500032648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300294","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630824728","title":"图解博雅生物一季报:第一季度单季净利润同比下降78.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630824728","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630824728?lang=zh_cn&edition=full","pubTime":"2026-04-25 03:17","pubTimestamp":1777058238,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物2026年一季报显示,一季度公司主营收入3.21亿元,同比下降40.07%;归母净利润3022.09万元,同比下降78.33%;扣非净利润2032.35万元,同比下降80.13%;负债率11.22%,投资收益393.33万元,财务费用-1006.81万元,毛利率46.26%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500008999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186809146","title":"华润医药旗下博雅生物季度营收32.11亿元 净利润达3000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186809146","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186809146?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:19","pubTimestamp":1777033154,"startTime":"0","endTime":"0","summary":"华润医药集团旗下控股子公司博雅生物最新季度财务数据显示,公司实现未经审计营业收入32.11亿元人民币,净利润录得3000万元。作为血液制品行业的领军企业,博雅生物本季度业绩展现出稳健的经营态势。\n从财务结构来看,公司营收规模保持较高水平,净利润表现符合市场预期。在医药行业政策持续优化的背景下,博雅生物通过精细化管理和技术创新,持续巩固其在血液制品领域的技术优势和市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300294","BK0197","BK1570","BK1191","03320","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779778995848,"stockEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":-0.1444},{"period":"3month","weight":-0.2841},{"period":"6month","weight":-0.3345},{"period":"1year","weight":-0.396},{"period":"ytd","weight":-0.2977}],"compareEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":0.0178},{"period":"3month","weight":0.0085},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.2402},{"period":"ytd","weight":0.0463}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31639人(较上一季度减少0.41%)","perCapita":"15937股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":" 华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、人免疫球蛋白、静注人免疫球蛋白(含10%高浓度剂型)、冻干静注人免疫球蛋白、乙肝人免疫球蛋白、破伤风免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血酶原复合物、人凝血因子Ⅷ。公司技术实力雄厚,先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项,拥有各类专利200余项,多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}